Resumen

ARAGONES EROLES, AM et al. Efavirenz plasma levels and dyslipidemia. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.1, pp.64-69.  Epub 07-Jun-2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20210001000014.

The aim of this study is to evaluate if there is a relationship between plasma levels of efavirenz and the occurrence of dyslipidemia such as hypercholesterolemia, hypretrigiceridemia or increased LDL-c.

Plasma levels of efavirenz were performed to patients under treatment with this drug during the period from September 2012 to June 2015. Lipid parameters corresponding to each analytical were recorded. Determinations of efavirenz were analyzed by high performance liquid chromatography. Data were managed using the Quick Statistics Calculator and Excel 2007 program.

Plasma levels of efavirenz higher than 4,000 ng/ml were associated, in our study, with a higher frequency of cholesterol levels higher than 200 mg/dl.

This study may be useful to those areas where treatment guidelines with this drug are used on a frequent basis.

Palabras clave : Efavirenz; dyslipidemia; adverse drug reaction; therapeutic drug monitoring.

        · resumen en Español     · texto en Español     · Español ( pdf )